Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma Our study included a broad cohort of ...

Widely regarded as a founder of cell free DNA (cfDNA) technology, Professor Dennis Lo is now pioneering investigation into the emerging science of fragmentomics. If you were at were at our recent ...

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, largely because it is rarely caught early and diagnosed too late for curative treatment. The five-year survival rate ...

LOS ANGELES and AMSTERDAM, April 30, 2024 (GLOBE NEWSWIRE) -- RenovaroCube, wholly owned subsidiary of Renovaro, Inc. (Nasdaq: RENB), a company at the forefront of AI-driven healthcare innovation, ...

Biomarkers have become essential in the diagnosis and treatment of cancer, so it’s no surprise there is a race underway to uncover more of them. Cancer biomarkers—which include inherited or acquired ...

Cell-free DNA (cfDNA) analysis is transforming precision medicine, offering a non-invasive window into the body, particularly in the context of cancer. This journal collection, hosted by npj Precision ...

Researchers at City of Hope, and at the Translational Genomics Research Institute (TGen), have developed and tested a machine-learning approach that they suggest could one day enable earlier ...